GG is a manufacturing entity which produces and sells a range of products. GG's trial balance at 30 September 2020 is shown below: R000 ROOO Administrative expenses 910 Borrowings @ 7% per year 3.000 Buildings at cost at 30 September 2019 3,400 Cash and cash equivalents 130 Cash received on disposal of machinery (1) 8 Cost of raw materials purchased to 30 September 2020 2,220 Direct production labour costs 670 Distribution costs 515 Equity dividend paid 170 Equity shares R1 each, fully paid at 30 September 2020 (xi) 1,700 Income tax (vill) 30 Inventory of finished goods at 30 September 2019 (vii) 190 Inventory of raw materials at 30 September 2019 (vii) 275 Land at valuation at 30 September 2019 (ii) 9,000 Loan interest paid 210 Plant and equipment at cost at 30 September 2019 (1) 3.900 Production overheads (excluding depreciation) 710 Provision for deferred tax at 30 September 2019 (ix) 430 Accumulated depreciation at 30 September 2019: Buildings 816 Plant and equipment (iv) 2.255 Patent 526 Retained earnings at 30 September 2019 3,117 Revaluation reserve at 30 September 2019 1.800 Sales revenue 9.820 Share premium 100 Trade payables 940 Trade receivables 1.130 23,986 23,986 Additional information: i) During the year GG disposed of obsolete machinery for R8,000. The cash received is included in the trial balance. The obsolete machinery had originally cost R35,000 and had accumulated depreciation of R32,000. ii) On 30 September 2020 GG revalued its land to R9,500,000 330 il) Buildings are depreciated at 2% per annum on the straight line basis. Buildings depreciation should be treated as an administrative expense. No buildings were fully depreciated at 30 September 2019. iv) Plant and equipment is depreciated at 25% per annum using the reducing balance method and is treated as a production overhead. V) The patent for one of GG's products was purchased on 1 October 2017. The patent had a useful life of 10 years when it was purchased and is being amortised on a straight line basis with no residual value anticipated. Amortisation of the patent is treated as cost of sales when charged to the income statement. Research is carried out on a continuous basis to develop the patented process and ensure that the product range continues to meet customer demands. The patent figure in the trial balance is made up as follows: R000 Original cost of patent 420 less amortisation to 30 September 2019 (84) 336 Research costs incurred in the year to 30 September 2020 Total 190 526 vi) GG's accounting policy for amortisation and depreciation is to charge a full year in the year of acquisition and none in the year of disposal. vii) Inventory of raw materials at 30 September 2020 was R242,000. Inventory of finished goods at 30 September 2020 was R180,000 viii) The directors estimate the income tax charge on the year's profits at R715,000. The balance on the income tax account represents the under-provision for the previous year's tax charge. ix) The deferred tax provision is to be reduced by R47,000. x) GG entered into a non-cancellable 4 year operating lease on 1 October 2019, to acquire machinery to replace the old machinery sold. Under the terms of the lease GG will pay no rent for the first year. R8,000 is payable for each of 3 years commencing on 1 October 2020. The machine is estimated to have a useful economic life of 10 years. xi) During the year GG issued 200,000 R1 equity shares at a premium of 50%. The total proceeds were received before 30 September 2020 and are reflected in the trial balance figures. Required: Prepare GG's statement of comprehensive income and a statement of changes in equity for the year to 30 September 2020 and a statement of financial position at that date, in accordance with the requirements of International Financial Reporting Standards. (All workings should be to the nearest R000). Notes to the financial statements are not required, but all workings must be clearly shown. Do not prepare a statement of accounting policies